​

Xeris Biopharma (XERS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

XERS Stock Forecast

Xeris Biopharma (XERS) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $5.20, with a high of $6.60 and a low of $4.00. This represents a 26.52% increase from the last price of $4.11.

$1 $2 $3 $4 $5 $6 $7 High: $6.6 Avg: $5.2 Low: $4 Last Closed Price: $4.11

XERS Stock Rating

Xeris Biopharma stock's rating consensus is Buy, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (88.89%), 1 Hold (11.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 9 0 1 8 Strong Sell Sell Hold Buy Strong Buy

XERS Price Target Upside V Benchmarks

TypeNameUpside
StockXeris Biopharma26.52%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts-14
Avg Price Target-$4.00$4.65
Last Closing Price$4.11$4.11$4.11
Upside/Downside--2.68%13.14%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25141--6
Mar, 25141--6
Feb, 25141--6
Jan, 25141--6
Dec, 24241--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 07, 2025Piper Sandler$4.00$4.24-5.66%-2.68%
Nov 11, 2024Oren LivnatH.C. Wainwright$6.60$3.25103.08%60.58%
Oct 23, 2024Leland GershellOppenheimer$5.00$3.0265.56%21.65%
May 10, 2024David AmsellemPiper Sandler$3.00$1.8562.16%-27.01%
Apr 28, 2022Craig-Hallum$6.50$2.33178.97%58.15%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 07, 2025Craig-HallumBuyBuyhold
Mar 07, 2025Piper SandlerNeutralNeutralhold
Mar 07, 2025H.C. WainwrightBuyBuyhold
Nov 11, 2024H.C. WainwrightBuyBuyhold
Nov 11, 2024Piper SandlerOverweightNeutraldowngrade
Oct 23, 2024OppenheimerOutperformOutperformhold
Aug 09, 2024Craig-HallumBuyBuyhold
May 10, 2024Piper SandlerOverweightOverweighthold
Apr 28, 2022Craig-HallumBuyinitialise
Jan 02, 2022SVB LeerinkOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported$-2.88$-1.20$-0.70$-0.45-
Avg Forecast$-2.14$-1.22$-0.42$-0.39$-0.22
High Forecast$-1.96$-1.12$-0.36$-0.36$-0.05
Low Forecast$-2.24$-1.28$-0.48$-0.43$-0.30
Surprise %34.58%-1.64%66.67%15.38%-

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 20 Dec 21 Dec 22 Dec 23 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported$49.59M$110.25M$110.25M$163.91M-
Avg Forecast$22.03M$47.47M$165.00M$162.58M$239.25M
High Forecast$22.86M$49.26M$179.31M$163.59M$260.00M
Low Forecast$20.64M$44.47M$150.41M$161.88M$218.10M
Surprise %125.09%132.25%-33.18%0.82%-

Net Income Forecast

$-350M $-280M $-210M $-140M $-70M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 23 Dec 24
Dec 20Dec 21Dec 22Dec 23Dec 24
Reported$-122.72M$-94.66M$-94.66M$-62.26M-
Avg Forecast$-294.62M$-167.69M$-57.82M$-54.18M$-30.29M
High Forecast$-270.40M$-153.90M$-49.56M$-49.61M$-6.88M
Low Forecast$-309.08M$-175.91M$-66.08M$-58.75M$-41.30M
Surprise %-58.35%-43.55%63.71%14.91%-

XERS Forecast FAQ

Is Xeris Biopharma stock a buy?

Xeris Biopharma stock has a consensus rating of Buy, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Xeris Biopharma is a favorable investment for most analysts.

What is Xeris Biopharma's price target?

Xeris Biopharma's price target, set by 9 Wall Street analysts, averages $5.2 over the next 12 months. The price target range spans from $4 at the low end to $6.6 at the high end, suggesting a potential 26.52% change from the previous closing price of $4.11.

How does Xeris Biopharma stock forecast compare to its benchmarks?

Xeris Biopharma's stock forecast shows a 26.52% upside, underperforming the average forecast for the healthcare stocks sector (35.25%) and underperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Xeris Biopharma over the past three months?

  • April 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Xeris Biopharma’s EPS forecast?

Xeris Biopharma's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.22, marking a -51.11% decrease from the reported $-0.45 in 2023..

What is Xeris Biopharma’s revenue forecast?

Xeris Biopharma's average annual revenue forecast for its fiscal year ending in December 2024 is $239.25M, reflecting a 45.96% increase from the reported $163.91M in 2023.

What is Xeris Biopharma’s net income forecast?

Xeris Biopharma's net income forecast for the fiscal year ending in December 2024 stands at $-30.288M, representing a -51.35% decrease from the reported $-62.255M in 2023.